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Wei Sun1,2†, Wei-Jin Li1,2†, Chang-You Wu3, Hua Zhong1,2 and Wei-Ping Wen1,2*Abstract
Background: T regulatory cells (Tregs) contribute to the progression of head and neck squamous cell carcinoma
(HNSCC) by suppressing antitumor immunity. However, little is known regarding the functional heterogeneity of
Tregs in HNSCC patients.
Methods: Using multicolor flow cytometry, the frequency of three Treg subsets, separated on the basis of CD45RA
and Foxp3, from the peripheral circulation of newly-presenting HNSCC patients (19 oral cavity squamous cell
carcinoma, 20 hypopharyngeal squamous cell carcinoma, 18 nasopharyngeal squamous cell carcinoma, 19 oropharyngeal
squamous cell carcinoma, and 36 laryngeal squamous cell carcinoma) were assessed with regard to 31 healthy donors
and clinicopathological features. Moreover, the functional capacity of each Treg subsets was evaluated based on CD45RA
and CD25 expression.
Results: The frequency of Tregs in the peripheral circulation of HNSCC patients as a whole cohort was higher than in
healthy donors (P < 0.0001). However, the frequency of Tregs was similar between patients with oral cavity squamous cell
carcinoma and healthy donors (P = 0.269). Further dividing Tregs into three subsets based on Foxp3 and CD45RA
expression revealed that the frequency of CD45RA−Foxp3high Tregs and CD45RA−Foxp3lowCD4+ T cells in patients with
HNSCC developing from different subsites was higher than in healthy donors (P < 0.0001, P < 0.0001), whereas the
frequency of CD45RA+Foxp3low Tregs was lower than in healthy donors (P < 0.0001). Functionally study revealed that
CD45RA−CD25+++ Tregs significantly inhibit the proliferation of CD4+CD25− T cells (P < 0.001) and secrete lower levels of
cytokines (P < 0.01) compared with CD45RA−CD25++CD4+ T cells. Importantly, the frequency of CD45RA−Foxp3high Tregs
positively correlate with tumor stage (P < 0.0001) and nodal status (P < 0.0001).
Conclusions: CD45RA−Foxp3high Tregs increase in the peripheral circulation of HNSCC patients, and correlate with tumor
stage and nodal status; suggesting a role in tumor progression which may be manipulated by future immunotherapy.
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Table 1 Clinicopathological features of 112 HNSCC
patients who donated peripheral blood for this study
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HNSCC, Head and neck squamous cell carcinoma.
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Globally, head and neck cancer is the sixth most com-
mon type of cancer [1]. Approximately 90% of head
and neck cancer cases arise from organs lined by squa-
mous epithelium [2]. Despite new treatment modalities
(including surgical and adjuvant chemoradiotherapy)
and their success in terms of overall quality of life, sur-
vival rates for this disease have not improved in the
past 30 years [3].
It is widely recognized that the progression of head
and neck squamous cell carcinoma (HNSCC) is attrib-
uted to the peripheral immune tolerance to tumors [4].
Foxp3+CD25+CD4+ T regulatory cells (Tregs), with im-
munosuppressive activity against tumor-specific T cell
responses, are one of the crucial players for immune tol-
erance [5,6].
To date, Tregs have been shown to be elevated in a
number of different cancers [7-13], including HNSCC
where it has been reported that Tregs increase in the
peripheral circulation when compared with healthy donors.
However, Tregs are not functionally homogeneous [14]. For
example, Zhou et al. [15] showed that CD4+Foxp3− T cells
could transiently express lower levels of Foxp3 and leads to
the generation of pathogenic memory T cells. Allan et al.
[16] postulated that activated CD4+ T cells, but without
regulatory activity, could express Foxp3. Hence, identifica-
tion of distinct Treg subsets and their functional abilities
might be more intriguing in antitumor immunity field.
Recently, Sakaguchi’s group demonstrated that human
Tregs can be dissected into three functionally distinct
subsets on the basis of CD45RA, Foxp3 and CD25
expression: CD45RA+Foxp3low Tregs (resting Tregs),
which are CD25++, CD45RA−Foxp3high Tregs (activated
Tregs), which are CD25+++, and CD45RA−Foxp3lowCD4+
T cells (cytokine-secreting non-suppressive T cells), which
are CD25++ [14]. Based on this classification of human
Tregs, subsequent studies showed that the frequency and
function of these Treg subsets vary in different disease
models, including systemic lupus erythematosus, sarcoid-
osis, and aplastic anemia [14,17,18]. However, the charac-
terizations of these functionally distinct Treg subsets in
HNSCC are unknown.
When assessing the Treg subsets it is important not
only to examine their characteristics in HNSCC patients
as a whole cohort, but also to investigate their variations
in patients with HNSCC developing from different ana-
tomic subsites, as the various subsites of HNSCC are
known to have different etiology and survival rates. To
our knowledge, this is the first study to use the
CD45RA, Foxp3, and CD25 markers to study both the
frequency and function of three distinct Treg subsets in
the peripheral circulation of newly-presenting HNSCC
patients in relation to tumor subsites, tumor stage and
nodal status.Materials and methods
Patients and healthy donors
From September 2012 to February 2014, 112 HNSCC
patients were enrolled in the present study [19 oral cavity
squamous cell carcinoma (OCSCC), 20 hypopharyngeal
squamous cell carcinoma (HPSCC), 18 nasopharyngeal
squamous cell carcinoma (NPSCC), 19 oropharyngeal
squamous cell carcinoma (OPSCC), and 36 laryngeal
squamous cell carcinoma (LSCC)]. Patients were diag-
nosed at the Department of Otorhinolaryngology, the First
Affiliated Hospital of Sun Yat-sen University without any
previous oncological treatment. Healthy age-matched do-
nors (29 males and 2 female with a mean age of 45 years;
range: 38–81) were enrolled as controls. The main clinical
and pathologic characteristics of the patients are presented
in Table 1. Clinical staging and the anatomic subsites of
the tumors were assessed according to the 6th edition of
the Union Internationale Contre Cancer (UICC 2008)
tumor-node-metastasis classification of malignant tumors.
Ethics statements
The study protocol (No. 2012–349) was approved by the
ethic Committee of The First Affiliated Hospital of Sun
Yat-sen University, and was used for research purposes
only. Patient and healthy donor (HD) informed consent
was obtained before enrollment.
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Peripheral blood lymphocytes (PBLs) were isolated from
peripheral venous blood as previously described [19].
Isolated cells were immediately re-suspended in 100 μl
flow cytometry staining buffer (eBioscience, San Diego,
CA, USA) for surface and intracellular staining.
Antibodies and reagents
Freshly obtained human PBLs were stained with the
following anti-human monoclonal antibodies: anti-
CD3-eFluor 605NC (0.25 μg/100 μl), anti-CD4-FITC
(1.0 μg/100 μl), anti-CD25-APC (0.125 μg/100 μl), and
anti-CD45RA-eFluor 450 (0.5 μg/100 μl) for surface
staining. Anti-Foxp3-PE (0.25 μg/100 μl), anti-tumor
necrosis factor-alpha (TNF-α)-Alexa Fluor 700 (0.25 μg/
100 μl), anti-interleukin-2 (IL-2)-PE-Cy7 (0.125 μg/100 μl),
anti-interferon-gamma (IFN-γ)-APC-eFluor780 (0.25 μg/
100 μl), and anti-hinterleukin-17 (IL-17)-PerCP-Cy5.5
(0.125 μg/100 μl) for intracellular staining. Soluble anti-
CD3 (OKT3, 0.5 μg/ml) and anti-CD28 (CD28.2, 2 μg/
ml) mAb were used for in vitro activation of T cells. All
antibodies and isotype controls were purchased from
eBioscience (San Diego, CA, USA).
Multicolor flow cytometry
Multicolor flow cytometry was done using a Ten-Color
(3 laser: 488 nm blue, 638 nm red, and 405 nm violet)
Gallios Flow Cytometer (Beckman Coulter, Hercules, CA,
USA) equipped with Gallios Software v1.0. The acquisition
and analysis gates for PBLs (5 × 104) were determined by
characteristic forward and side-scatter properties of lym-
phocytes. Furthermore, analysis gates were restricted to
the CD3+CD4+ T-cell subsets. CD45RA+Foxp3low Tregs
(I), CD45RA−Foxp3high Tregs (II), and Foxp3lowCD45RA−
T cells (III) were determined as previously described [14].
Cells expressing surface and intracellular markers were
acquired and analyzed on a logarithmic scale from FL1
to FL9.
Surface and intracellular staining
To determine the frequency of three distinct Treg sub-
sets, both cell surface and intracellular staining was
performed. Briefly, mAbs against surface markers CD3,
CD4, CD25, and CD45RA were added to the cell suspen-
sion (1 × 107 cells/100 μl) and incubated on ice for 30 -
minutes in the dark. After washing twice, cells were fixed
and permeabilized on ice with fixation/permeabilization
buffer (eBioscience, San Diego, CA, USA) for 1 hour in
the dark. Cells were then washed twice and incubated with
intracellular mAbs for 1 hour at room temperature in the
dark. After intracellular staining, cells were washed twice
and examined by multicolor flow cytometry. Appropriate
isotype Ab controls were included for each sample.Cell culture
RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100 IU/ml penicillin, and 100 mg/ml streptomycin
(Sigma, St. Louis, MO) was used for T cell culture.
In vitro suppression assay of three distinct Treg subsets
Stained cells (mAbs against CD3, CD4, CD25, and
CD45RA) at a concentration of 5 × 107 cells/100 μl
were sorted using a FACS cell sorter (BD Influx, BD
Biosciences). Three Treg subsets were prepared as live cells
as previously described [14]; i.e., Foxp3lowCD45RA+ (I),
Foxp3highCD45RA− (II), and Foxp3lowCD45RA− cells
(III) were prepared by sorting as CD25++CD45RA+,
CD25+++CD45RA−, and CD25++CD45RA−CD4+ T cells,
respectively. For HNSCC patients, Additional file 1:
Figure S1 demonstrates that the degree of CD25 expres-
sion in CD45RA+CD25++ Tregs, CD45RA−CD25+++
Tregs, and CD45RA−CD25++CD4+ T cells are pro-
portional to Foxp3 expression in CD45RA+Foxp3low
Tregs, CD45RA−Foxp3high Tregs, and CD45RA−Fox-
p3low CD4+ T cells, respectively.
After sorting, 1 × 104 responder cells (CD25−CD45RA+
CD4+ T cells) were labeled with 1 μM carboxyfluorescein
diacetate succinimidyl ester (CFSE) (eBioscience, San
Diego, CA, USA) and co-cultured with unlabeled CD25++
CD45RA+, CD25+++CD45RA−, or CD25++CD45RA− CD4
+ T cells and assessed for their suppressive activities.
Soluble anti-CD28 (2 μg/ml) and plate-bound anti-CD3
(0.5 μg/ml) was used to activate T cells in 96-well round-
bottom plates, and cells harvested and analyzed by flow
cytometry after 86 h of co-culture. All CFSE data were
analyzed using the ModFit software provided by Verity
Software House (Topsham, USA). The percentages of sup-
pression were determined based on the proliferation index
(PI) of responder cells alone (100% proliferation, 0% sup-
pression) compared with the PI of responders co-cultured
(1:1 ratio) with each Treg subset.
Secretory functions of three distinct Treg subsets
To examine secretory function, sorted CD25++CD45RA+,
CD25+++CD45RA−, or CD25++CD45RA− CD4+ T cells
were stimulated with a cocktail of phorbol 12-myristate 13-
acetate (PMA), ionomycin, and Golgi stop (brefeldin A and
monensin) (eBioscience, San Diego, CA, USA) for 5 h.
Then, intracytoplasmic expression of IL-2, IL-17, TNF-α,
and IFN-γ were assessed using intracellular staining.
Statistical analysis
Statistical analysis was performed with the SPSS software
(SPSS Standard version 13.0, IBM, Chicago, IL, USA). The
Mann–Whitney U-test or Kruskal–Wallis test was used for
analyzing differences between data sets without normal dis-
tribution. Differences between independent data sets, with
normal distribution, were analyzed using the Student's t-test.
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Prevalence of three distinct Treg subsets in the peripheral
circulation of 112 HNSCC patients
Figure 1A illustrates the gating strategy used to identify
the frequency of CD25+Foxp3+ Tregs in the total CD3Figure 1 Percentage of Treg subsets in 112 HNSCC patients. (A) Gatin
for one representative HD (left) and HNSCC patient (middle). Percentage (m
(C) Flow dot plots of each Treg subset (I: CD45RA+Foxp3low Tregs; II: CD45RA
HD (left) and HNSCC patient (right). (D) Percentage (means ± SD) of each Treg
carcinoma. HD: healthy donors. Statistical comparisons were performed using+CD4+ T cells. The frequency of these Tregs in the per-
ipheral circulation of HNSCC patients as a whole cohort
was higher than in HD (8.12 ± 2.34% vs. 5.44 ± 1.92%,
P < 0.0001) (Figure 1B), consistent with previous find-
ings [10]. The frequency of three Treg subsets was theng strategy used is illustrated. (B) Flow dot plots of Foxp3+CD25+ Tregs
eans ± SD) of Foxp3+CD25+ Tregs in HNSCC patients or HD (right).
−Foxp3high Tregs; III: CD45RA−Foxp3lowCD4+ T cells) for one representative
subset in HNSCC patients or HD. HNSCC: head and neck squamous cell
the Mann–Whitney U-test.
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novelty of this study was that the frequency of CD45RA
−Foxp3high Tregs (2.23 ± 0.98% vs. 0.77 ± 0.49%, P < 0.0001)
and CD45RA−Foxp3lowCD4+ T cells (5.36 ± 1.63% vs. 3.70
± 1.58%, P < 0.0001) in HNSCC patients was higher than in
HD, whereas the frequency of CD45RA+Foxp3low Tregs in
HNSCC patients was lower than in HD (0.53 ± 0.24% vs.
0.98 ± 0.61%, P < 0.0001) (Figure 1C, D).
Suppressive and secretory function of three distinct Treg
subsets
The suppressive activity of each Treg subset from 12
randomly selected HNSCC patients was assessed by
their ability to suppress the proliferation of autologous T
cell populations (CD25−CD45RA+CD4+). When each Treg
subset isolated from HNSCC patients was co-cultured
(1:1 ratio) with CD25−CD45RA+CD4+ responder cells,
both CD45RA−CD25+++ and CD45RA+CD25++ Tregs
consistently induced a greater percentage of suppres-
sion compared with CD45RA−CD25++CD4+ T cells
(90.34 ± 3.22% vs. 10.81 ± 1.64%, P < 0.001; 88.60 ± 4.86%
vs. 10.81 ± 1.64%, P < 0.001, respectively) (Figure 2A-E).
However, each Treg subset didn’t inhibit the cytokine
production by responder cells (P > 0.05) (Additional
file 2: Figure S2), which is in parallel with previous
studies [20,21].
Moreover, functional cytokine patterns in three Treg
subsets from 9 HNSCC patients were also studied after
ex vivo stimulation. Our results showed that CD45RA
−CD25++CD4+ T cells secreted significantly higher amount
of IL-2 (P = 0.004, P = 0.01), IFN-γ (P < 0.001, P < 0.001)
and TNF-α (P < 0.001, P = 0.005) than did CD45RAFigure 2 Percentage of suppression by each Treg subset on the proli
CD4+CD25−CD45RA+ T cells (responder T cells) assessed after 86 hr of TCR-
plots for one representative HNSCC patient. Percentage of suppression is in
(parent line) and the generation population (generation line) 1, 2, 3… from
suppression ± SD (n = 12). HNSCC: head and neck squamous cell carcinom−CD25++ or CD45RA+CD25++ Tregs, whereas IL-17 pro-
duction remained the same (P > 0.05) (Figure 3A, B).Prevalence of three distinct Treg subsets in HNSCC
patient subgroups
Dividing the HNSCC patient cohort by tumor subsite
demonstrated that the frequency of Tregs in patients with
OPSCC (8.93 ± 1.49%, P < 0.0001), LSCC (8.09 ± 1.66%,
P < 0.0001), HPSCC (9.68 ± 1.94%, P < 0.0001), and
NPSCC (8.58 ± 2.62%, P < 0.0001) was higher than in
HD (5.44 ± 1.92%). However, the frequency of Tregs was
similar between OCSCC patients and HD (5.70 ± 1.56%
vs. 5.44 ± 1.92%, P = 0.269).
The frequency of CD45RA−Foxp3high Tregs in patients
with OCSCC (1.06 ± 0.36%, P = 0.006), OPSCC (2.54 ±
0.42%, P < 0.0001), LSCC (2.36 ± 0.92%, P < 0.0001), HPSCC
(2.51 ± 0.76%, P < 0.0001), and NPSCC (2.69 ± 1.12%, P <
0.0001) was higher than in HD (0.77 ± 0.49%), whereas the
frequency of CD45RA+Foxp3low Tregs in patients with
OCSCC (0.39 ± 0.17%, P < 0.0001), OPSCC (0.52 ± 0.16%,
P = 0.002), LSCC (0.62 ± 0.28%, P = 0.008), HPSCC (0.58 ±
0.24%, P = 0.003), and NPSCC (0.55 ± 0.21%, P = 0.002) was
lower than in HD (0.98 ± 0.61%).
The frequency of CD45RA−Foxp3lowCD4+ T cells in pa-
tients with OPSCC (5.86 ± 1.26%, P < 0.0001), LSCC (5.10 ±
1.14%, P < 0.0001), HPSCC (6.63 ± 1.67%, P < 0.0001), and
NPSCC (5.37 ± 1.66%, P = 0.002) were higher than in HD
(3.70 ± 1.58%). However, the frequency of CD45RA
−Foxp3lowCD4+ T cells was similar between OCSCC
patients (4.24 ± 1.31%) and HD (3.70 ± 1.58%) (P = 0.093)
(Figure 4A-C).feration of responder T cells. (A-D) CFSE dilution by 1 × 104 labeled
stimulated co-culture with indicated Treg subset at a 1 to 1 ratio. Flow
dicated. In each histogram, the lines indicate the parent population
right to left. (E) The histogram represents the mean percentages of
a. Statistical comparisons were performed using the Student’s t-test.
Figure 3 Cytokine production of each Treg subset. (A) Production of IL-17, IL-2, IFN-γ, and TNF-α by each Treg subset after stimulation
with PMA + ionomycin, and percentage of cytokine-secreting cells in each Treg subset is shown. Data are representative of 9 separate
experiments. (B) The histogram represents the cytokine expression profiles of each Treg subset. Statistical comparisons were performed
using the Student’s t-test.
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The frequency of CD45RA−Foxp3high Tregs in patients with
OPSCC (2.54 ± 0.42%, P < 0.0001), LSCC (2.36 ± 0.92%,
P < 0.0001), HPSCC (2.51 ± 0.76%, P < 0.0001), and NPSCC
(2.69 ± 1.12%, P < 0.0001) was higher than in OCSCC pa-
tients (1.06 ± 0.36%). There was no significant difference in
the frequency of CD45RA−Foxp3high Tregs betweenpatients with OPSCC, LSCC, HPSCC, and NPSCC (P >
0.05). Moreover, there was no significant difference in the
frequency of CD45RA+Foxp3low Tregs between patients
with OCSCC, OPSCC, LSCC, HPSCC, and NPSCC (P >
0.05). The frequency of CD45RA−Foxp3lowCD4+ T cells
in HPSCC patients was higher than in OCSCC patients
(6.63 ± 1.67% vs. 4.24 ± 1.31%, P < 0.0001) (Figure 4B).
Figure 4 Percentage of Treg subsets in HNSCC patient subgroups. (A) Flow dot plots of Tregs (Foxp3low and Foxp3high Tregs) (top) and
each Treg subset (I: CD45RA+Foxp3low Tregs; II: CD45RA−Foxp3high Tregs; III: CD45RA−Foxp3lowCD4+ T cells) (bottom) for one representative
HD and patients with HPSCC, NPSCC, OPSCC, and LSCC. (B) Percentage (means ± SD) of Tregs and each Treg subset in HNSCC patient
subgroups or HD. (C) Different proportions (means) of each Treg subset in HNSCC patient subgroups are presented. HD: healthy donors.
OCSCC: oral squamous cell carcinoma. HPSCC: hypopharyngeal squamous cell carcinoma. NPSCC: nasopharyngeal squamous cell carcinoma.
OPSCC: oropharyngeal squamous cell carcinoma. LSCC: laryngeal squanmous cell carcinoma. Statistical comparisons were performed using
the Kruskal–Wallis test.
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progression
The frequency of CD45RA−Foxp3high Tregs in patients with
T3–4 or N
+ was higher than in patients with T1–2 or N0,
respectively (T3–4 vs. T1–2: 2.81 ± 0.89% vs. 1.83 ± 0.82%,
P < 0.0001; N+ vs. N0: 2.92 ± 1.03% vs. 1.81 ± 0.65%, P <
0.0001).
The frequency of CD45RA+Foxp3low Tregs did not dif-
fer between patients with T3–4 and T1–2 (0.52 ± 0.18% vs.
0.54 ± 0.28%, P = 0.834) or with N+ and N0 (0.50 ± 0.17%
vs. 0.55 ± 0.17%, P = 0.556). The frequency of CD45RA
−Foxp3lowCD4+ T cells in patients with T3–4 or N
+ was
higher than in patients with T1–2 or N0, respectively (T3–4
vs. T1–2: 6.26 ± 1.39% vs. 4.73 ± 1.49%, P < 0.0001; N
+ vs.
N0: 6.07 ± 1.81% vs. 4.93 ± 1.36%, P < 0.0001) (Table 2).
Discussion
Tregs have been suggested to contribute to HNSCC
progression by suppressing antitumor immunity [4]. Al-
though Tregs in the peripheral circulation of HNSCC
patients have been investigated previously, most of these
studies were focused on the frequency and suppressive
function of CD25+ Tregs or CD25high Tregs [10,22-24],
and the functional heterogeneity of Tregs was not fully in-
vestigated. To expand the understanding of functionally
distinct Treg subsets in HNSCC, we recruited a cohort of
112 newly-presenting HNSCC patients that had not re-
ceived any previous treatment for cancer. The use of the
CD45, Foxp3, and CD25 markers has allowed both the
frequency and the function of three distinct Treg subsets
in the circulation of HNSCC patients with tumors of vary-
ing stage and nodal status to be determined.
There is evidence that Tregs are negative prognostic
factors for patients with types of human malignancies
[7,8,25]. In contrast to these results, however, previous
studies of Tregs in HNSCC showed different conclu-
sions. For example, Pretscher et al. [26] showed that
higher levels of Tregs do not show any significant influ-
ence on outcome of oro- and hypopharyngeal carcinoma
patients, and other HNSCC studies even showed that
expansion of Tregs is significant prognostic factor re-
lated to better locoregional control and overall survival
[27,28]. This apparent confusion regarding the role of
Tregs in prognosis of cancer patients might be explainedTable 2 Relationship between Treg subsets and tumor progre
CD45RA−Foxp3high P CD45RA+ F
Tregs (%) Tregs
T1–2 1.83 ± 0.82 0.54 ± 0
T3–4 2.81 ± 0.89 <0.0001 0.52 ± 0
N0 1.81 ± 0.65 0.55 ± 0
N+ 2.92 ± 1.03 <0.0001 0.50 ± 0
Statistical comparisons were performed using the Mann–Whitney U-test.by the functional heterogeneity of Tregs or the nature of
tumor type, or some combination of the two.
Hence, to understand the heterogeneous role of Tregs,
Tregs in the peripheral circulation of 112 HNSCC pa-
tients were dissected into three functionally distinct
subsets based on the expression of CD45RA, Foxp3,
and CD25, and our results showed that although the fre-
quency of Tregs in HNSCC patients was higher than in
healthy age-matched donors, which is in agreement with
previous studies [10,22], both the frequency and function
of these three Treg subsets varied in HNSCC patients; i.e.,
the frequency of CD45RA−Foxp3high suppressive Tregs
in HNSCC patients was higher than in healthy donors,
whereas the frequency of CD45RA+Foxp3low Tregs was
lower, suggesting that CD45RA+Foxp3low Tregs may be
swiftly converted into CD45RA−Foxp3high Tregs immedi-
ately after migrating from the thymus or having been per-
ipherally generated [14]. Although we are not aware of
this phenomenon in human malignancies, the conversion
of CD45RA+Foxp3low Tregs to CD45RA−Foxp3high Tregs
has been found in other pathological conditions, such as
sarcoidosis [14].
Sakaguchis’s group defined CD45RA−Foxp3lowCD4+
T cells as cytokine-secreting non-Tregs for their ability
to secrete several cytokines (IL-2, IL-17, and IFN-γ). In
their disease models, including sarcoidosis and systemic
lupus erythematous, the frequency of CD45RA−Fox-
p3lowCD4+ T cells (non-Tregs) and CD45RA−Foxp3high
Tregs was reversed [14]. However, in our observations of
HNSCC, CD45RA−Foxp3lowCD4+ T cells were increased
in parallel with CD45RA−Foxp3high Tregs in HNSCC pa-
tients. We have found that this Treg subset secreted high
amount of effector cytokines, but did not have suppressive
activity in vitro. We hypothesized that the CD45RA−Fox-
p3lowCD4+ T cells could be a heterogeneous Treg subset
in HNSCC. They might be non-Tregs and could differenti-
ate into effector T cells as others have proposed [16]. The
increased frequency of this subset might be the result of
antigen exposure in tumor microenvironment [29]. Fur-
ther studies regarding the role of this subset in HNSCC,
including the function and differentiation, will be more
intriguing in future. Taken together, our data suggest
that we should carefully identify distinct Treg subsets
rather than the whole population of Tregs in the studyssion
oxp3low P CD45RA−Foxp3low P
(%) CD4+ T cells (%)
.28 4.73 ± 1.49
.18 0.834 6.26 ± 1.39 <0.0001
.17 4.93 ± 1.36
.17 0.556 6.07 ± 1.81 <0.0001
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the potential selective targeting factors in future HNSCC
immunotherapy.
HNSCC develop from anatomically defined locations
within the upper aerodigestive tract: larynx, hypopharynx,
oral cavity, oropharynx, nasopharynx, and nasal cav-
ity. Those tumors arising from different subsites are
frequently grouped together in previous research
studies [10,27,28], but the various subsites are known
to have different etiology and survival rates for the
same stage of disease. Hence, it should be necessary
to evaluate the variation of Tregs among HNSCC pa-
tient subgroups.
The present study showed that there was no significant
difference in the frequency of Tregs between OCSCC
patients and healthy donors. This is in contrast to the
majority of results reported by previous HNSCC studies
where Tregs have been found to be increased in the
cancer patients [10,22,30,31]. However, not all cancer
publications report an elevated trend, with some ob-
serving no significant difference in the frequency of
Tregs in the peripheral circulation of patients and
healthy donors, including one study examining oral
SCC [32,33]. It is perhaps not surprising that results
between studies are inconsistent, with the use of differ-
ent markers to identify Tregs and a heterogeneous can-
cer population. These biological and methodological
factors are likely to cause differences in reported Tregs
behavior. In spite of the above-described phenomenon,
we showed for the first time that the frequency of
CD45RA−Foxp3high Tregs with suppressive activity in
OCSCC patients was higher than in healthy donors.
Again, these findings suggest us to identify CD45RA
−Foxp3high Tregs rather than the whole population of
Tregs in the study of HNSCC.
In the study of the association between CD45RA−Fox-
p3high Tregs and tumor sites, the frequency of CD45RA
−Foxp3high Tregs was similar between patients with
HPSCC, NPSCC, OPSCC, and LSCC. These findings
were partially in parallel with previous HNSCC investi-
gations which showed that there was no significant
association between the frequency of Tregs and tumor
sites, including the larynx and oropharynx [24,33].
Although the frequency of CD45RA−Foxp3high Tregs
did not differ between patients with HPSCC, NPSCC,
OPSCC, and LSCC, it was found that HNSCC patients
with advanced stage tumors and those that metasta-
sized to the lymph nodes had significantly increased
levels of CD45RA−Foxp3high Tregs in comparison to
patients with early stage tumors and no nodal involve-
ment, respectively; in contrast to previous HNSCC
studies which found no differences [10,22-24]. However,
recent studies of HNSCC showed that CD127low/- Tregs
(including CD4+CD25interCD127low/- and CD4+CD25highCD127low/- Tregs) or CD4+CD25+Foxp3+ Tregs are associ-
ated with advanced stage and nodal involvement [33,34].
This is hypothesized to be due to the different phenotypes
used to identify Tregs and the composition of the patient
cohorts.
Conclusions
The present study provides evidence to support the
notion of heterogeneous Treg subsets in the peripheral
circulation of HNSCC patients. CD45RA−Foxp3high Tregs
(one distinct Treg subset) significantly increase in the per-
ipheral circulation of HNSCC patient subgroups. Import-
antly, CD45RA−Foxp3high Tregs positively correlate with
tumor progression. The present findings provide im-
portant information of the future design of immuno-
therapeutic strategies for HNSCC patients, for example
by monoclonal antibodies (anti-PD-1 Ab and anti-CTLA-
4 Ab), to reduce the expansion, survival and suppressive
function of the Tregs responsible for HNSCC-specific im-
mune suppression – as ever the problem remains effective,
specific targeting.
Additional files
Additional file 1: Figure S1. Relationship between expression levels of
CD25 vs. CD45RA and Foxp3 vs. CD45RA in PB CD4+ T cells of HNSCC
patients. The degree of CD25 expression in CD45RA + CD25++ Tregs (Fraction
1), CD45RA-CD25+++ Tregs (Fraction 2), and CD45RA-CD25++CD4+ T cells
(Fraction 3). (a) are proportional to Foxp3 expression in CD45RA +
Foxp3low Tregs (Fraction I), CD45RA-Foxp3high Tregs (Fraction II), and
CD45RA-Foxp3low CD4+ T cells (Fraction III), respectively (b). Gating
strategy used is illustrated as follows: CD45RA-CD25+ cells with red
background fluorescence (x-axis) were defined as CD45RA-CD25+ (CD25low).
The CD45RA + CD25++ (CD25inter) gate (Fraction 1) was adjusted to
contain CD45RA + T cells that express CD25 more brightly than
CD45RA-CD25+ (CD25low). The CD45RA-CD25+++ (CD25high) gate
(Fraction 2) was adjusted to contain CD45RAT cells exceeding the level
of CD25 expression on CD45RA + CD25++ (CD25inter) cells. The
CD45RA-CD25++ (CD25inter) gate (Fraction 3) was adjusted to contain
CD45RAT cells with the same level of CD25 expression as CD45RA + CD25++
(CD25inter) cells.
Additional file 2: Figure S2. Cytokine production by responder T cells.
The histograms represent the cytokine expression profiles of responder
cells co-cultured with CD45RA + CD25++, CD45RA-CD25+++, or Tregs
CD45RA-CD25++CD4+ T cells (P > 0.05). Data are representative of 9 separate
experiments. Statistical comparisons were performed using the Student’s
t-test.
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